Dr. Joaquin Mould-Quevedo, Global Pricing and Health Economics Director at Seqirus, a global leader in seasonal influenza prevention and pandemic influenza preparedness discusses data from two real-world studies demonstrating the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines. These findings were presented at Infectious Disease (ID) Week 2021 and further underscore the public health benefits of innovative technologies, including cell-based and adjuvanted technologies, in producing seasonal influenza vaccines, and reinforce the important role these vaccines play in reducing hospitalizations.
Dr. Joaquin Mould-Quevedo is the Global Pricing and Health Economics Director at Seqirus, a global leader in seasonal influenza prevention and pandemic influenza preparedness. At Seqirus, Joaquin provides leadership on Seqirus’ market access strategies to ensure broad payer coverage for Seqirus products. Prior to joining Seqirus, Joaquin was the Global Health Economics and Outcomes Research Director at Bayer Pharmaceuticals, overseeing its real-world evidence strategy within the oncology division. Joaquin was also previously with Pfizer and held the title of Health Economics and Outcomes Research Senior Director for Latin America and Primary Care.
Joaquin received his bachelor’s in economics from the University del Pacifico in Lima, Peru before earning his master’s in business administration from Paris University and his PhD in applied economics from the University of Alicante in Spain. Additionally, Joaquin has also developed advanced courses in pharmacoeconomics at the University of York in England.
Prior to joining the pharmaceutical industry, Joaquin worked at the Mexican Social Security Institute as a Health Economics researcher and was also President for the 2012-2014 Health Technology Producers Committee at the Latin American ISPOR Consortium.
Joaquin has performed over 200 pharmacoeconomics and outcomes research assessments and has over 70 publications of health economics and outcomes research topics in a variety of international, peer-reviewed journals. He has completed over 175 presentations at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meetings.